Giffin Brett A. 4
4 · T2 Biosystems, Inc. · Filed Nov 22, 2022
Insider Transaction Report
Form 4
Giffin Brett A.
Chief Commercial Officer
Transactions
- Sale
Common Stock
2022-11-10$1.79/sh−1,292$2,317→ 2,253 total - Exercise/Conversion
Common Stock
2022-11-08+3,333→ 3,545 total - Exercise/Conversion
Restricted Stock Units
2022-11-08−3,333→ 6,667 total→ Common Stock (3,333 underlying)
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]The sale reported in this Form 4 was made in order to pay the tax liability arising from vesting and settlement of RSU's on November 8, 2022. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the reporting person.
- [F3]On February 26, 2022 the reporting person was granted 10,000 RSU's that vest in three substantially equal installments on November 8, 2022, November 8, 2023, and October 1, 2024.